50 results about "Finasteride" patented technology

The invention discloses a hybrid vesicle composition containing finasteride and nanogold. The composition is prepared from hair follicle stem cell outer vesicles, lipidosome, finasteride and nanogold, according to the method, the treatment efficiency of finasteride on androgenetic alopecia is enhanced by utilizing the delivery property of a mediated hair recovery mechanism pathway and a homing effect of heterozygous hair follicle stem cell outer vesicles to a hair follicle microenvironment and assisting with a photothermal effect provided by nanogold light conversion, and the method can be widely applied to the fields of medical cosmetology and pharmacy.

The present invention relates to a novel long-acting injectable composition comprising finasteride for the prevention or treatment of androgenetic alopecia. The composition inhibits type II 5α-reductase with a single injection lasting over one month, thereby suppressing the conversion of testosterone to DHT and reducing androgen-mediated follicular miniaturization. In addition, after injection into the body, the average elimination half-life (T1 / 2el) of finasteride can be increased to enhance stability and provide more predictable and uniform therapeutic effects compared to oral formulations.

The invention relates to the technical field of pharmaceutical preparations, in particular to an external solution containing minoxidil and finasteride and a preparation method of the external solution. According to the external solution containing minoxidil and finasteride provided by the invention, the solvent and the penetration enhancer are added, so that the active ingredients of minoxidil and finasteride have higher retention volume in the skin, and can play a better role, thereby generating a more excellent hair growth effect.

The invention provides a pharmaceutical composition and application thereof in preparation of a compound preparation, and belongs to the field of medicines. The pharmaceutical composition comprises a potassium ion channel opener, a 5 alpha-reductase inhibitor and a phosphodiesterase 5 inhibitor. The pharmaceutical composition can synergistically promote treatment of androgen dependent diseases or prevention of complications, and by taking the pharmaceutical composition of minoxidil, finasteride and tadalafil as an example, the effects in a benign prostatic hyperplasia rat model and an androgenic alopecia mouse model are verified, which indicates that the minoxidil, finasteride and tadalafil have a synergistic interaction effect, and the pharmaceutical composition can be used for treating the androgen dependent diseases or preventing the complications. Good clinical application prospects are realized.

According to the foaming agent containing minoxidil and finasteride provided by the invention, micronization of raw material medicines and complicated preparation procedures such as homogenization are not needed in the preparation process, liquid medicine liquid is directly prepared and then is filled, and a propellant is added to prepare the foaming agent, so that the foaming agent has the advantages of few impurities, uniform medicine liquid and high stability; the invention has the advantages of strong foam adhesiveness, prolonged action time of the medicament on the scalp, uniform and non-greasy application, quick defoaming to enhance the curative effect, strong permeability, effective penetration of the medicament into the skin or mucous membrane to improve the bioavailability of the medicament, and the like. The preparation method is simple and easy to operate, time and cost can be greatly saved, meanwhile, the dosage form of the foaming agent has the advantages of being easy to smear, few in residue, capable of being smeared in a large area and the like, patient compliance is improved, use is convenient, the two active ingredients with different action mechanisms are in synergistic interaction, and the clinical effect is improved.

The invention discloses 5 alpha-reductase degradation molecules as well as a preparation method and application thereof, four 5 alpha-reductase degradation molecules can realize thorough removal of zymoprotein by inducing proteasome-dependent degradation of 5 alpha-reductase instead of only inhibiting the activity of the 5 alpha-reductase, so that a more lasting treatment effect is obtained; under the condition of equal dosage, the effect of the 5 alpha-reductase degradation molecule on treating the benign prostatic hyperplasia is superior to that of the traditional inhibitor finasteride; the four kinds of 5 alpha-reductase degrading molecules can effectively degrade 5 alpha-reductase protein and remarkably inhibit development of benign prostatic hyperplasia, have good biological safety and provide new strategies and candidate drugs for treatment of diseases related to 5 alpha-reductase such as benign prostatic hyperplasia, prostatic cancer, androgenetic alopecia and acne.

This disclosure relates to a single pharmaceutical composition comprising a therapeutically effective or prophylactically effective amount of both minoxidil, or a similar antihypertensive vasodilator, and a 5-alpha reductase inhibitor (in some embodiments, the 5-alpha reductase inhibitor is finasteride) for treating or preventing hair loss in a subject. This disclosure also relates to a pharmaceutical package comprising a pharmaceutical composition for oral administration of a therapeutically effective or prophylactically effective amount of minoxidil, or a similar antihypertensive vasodilator, and a pharmaceutical composition for oral administration comprising a therapeutically effective or prophylactically effective amount of a 5-alpha reductase inhibitor (in some embodiments, the 5-alpha reductase inhibitor is finasteride) for treating or preventing hair loss in a subject. The disclosure further provides methods of treating or preventing hair loss in a subject using the disclosed compositions and packages.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a minoxidil external preparation composition as well as a preparation method and application thereof. The invention provides a minoxidil external preparation composition. The minoxidil external preparation composition comprises minoxidil, finasteride, pharmaceutic adjuvants, organic acid, ethanol and water. By adding finasteride and pharmaceutic adjuvants, the treatment effect on alopecia is enhanced; by adding a proper amount of organic acid, the dissolution of minoxidil can be promoted in the absence of propylene glycol, so that the problem of replacing a propylene glycol solvent is solved. The minoxidil external composition prepared by the invention is stable, the treatment effect of the minoxidil external composition on alopecia is obviously higher than that of a solution only containing a minoxidil single component, and the minoxidil external composition does not contain a propylene glycol component, so that the occurrence of propylene glycol allergy is avoided. And the preparation method is simple, stable and good in reproducibility.

The invention belongs to the technical field of pharmaceutical analysis, and particularly relates to a biological analysis method for detecting the concentration of hydrocortisone butyrate in blood plasma, which is used for analyzing a compound to be detected in the blood plasma through an LC-MS / MS (Liquid Chromatography-Mass Spectrometry / Mass Spectrometry) method. According to the detection method, a liquid-liquid extraction pretreatment method is preferably adopted, finasteride serves as an internal standard substance, a Shim-pack Velox SP-C18 chromatographic column is adopted, gradient elution and electrospray ionization source tandem mass spectrometry detection are carried out, and the detection method is high in sensitivity, precise, accurate, high in analysis speed, high in sensitivity, high in sensitivity, high in sensitivity, high in sensitivity, high in sensitivity, high in sensitivity, high in sensitivity, high in sensitivity and high in sensitivity. The sample analysis requirement in the clinical research of the hydrocortisone butyrate is met.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses a tablet composition for treating alopecia areata and a preparation method thereof.The tablet composition is a composition comprising two main drugs including finasteride and baricitinib and is prepared by mixing and pressing finasteride particles and baricitinib particles which are prepared through specific auxiliary materials and a process, the finasteride granules and the baricitinib granules have good Karl index and Hausner ratio after being mixed, the pressed tablet composition has good performance in a plurality of test items such as acceleration for 6 months, long-term 6 months and high-humidity test, and the auxiliary material formula and the process can simultaneously meet the quality requirements of finasteride and baricitinib. Meanwhile, the degradation condition of the main medicine is relieved, the increase of related impurities of finasteride and baricitinib is reduced, the quality stability of the medicine under different storage conditions is improved, and the safety and effectiveness of the medicine within the period of validity and the integrity of the appearance of the tablet are ensured.

The application discloses a method for determining the content of forbidden components in anti-hair-loss cosmetics, and comprises the following steps: after sample treatment, machine determination is carried out, and an HPLC-MS / MS detection method is adopted, wherein: the liquid chromatography conditions are as follows: a chromatographic column is an Agilent ZORBAX SB-C18 (10 cm*4.6 mm, 3.5 um); a mobile phase A is 0.1% formic acid aqueous solution; a mobile phase B is acetonitrile; a flow rate is 0.6 mL / min; a column temperature is 25 DEG C; and a sample injection amount is 5 uL; and the forbidden components are finasteride and / or fluoroandrosterone. The method for determining the forbidden components in the anti-hair-loss cosmetics has high sensitivity, is simple and easy to operate, and has good repeatability, is a kind of detection method capable of accurately determining the nature and quantity, and has important significance for controlling the quality of the anti-hair-loss cosmetics.

A pharmaceutical formulation for treating alopecia, a preparation method therefor and the use thereof are provided. Specifically, a formulation or composition for treating alopecia contains the following active components on the basis of the mass percentage (w / w) or mass / volume percentage (w / v): (a) 5% of minoxidil; and (b) 0.07-0.095% of finasteride. The formulation or the composition is a foaming agent or a liniment. When the formulation is a foaming agent, the total mass in the mass percentage does not contain the mass of a propellant.

The invention provides a sustained-release medicinal preparation for preventing and treating alopecia as well as a preparation method and application of the sustained-release medicinal preparation, and belongs to the technical field of biological medicines. The medicine for preventing and treating alopecia is prepared from the following components: 1 to 2.5 mg of finasteride, 4 to 6 mg of minoxidil, 20 to 60 mg of spirolactone, 10 to 20 mg of isotretinoin, 3 to 8 mg of vitamin B5, 50 to 100 mg of zinc and 5 to 10 mg of vitamin b6. The components cooperate with one another to activate hair follicle stem cells, increase the number of hair follicles and synergistically enhance the ability of promoting hair regeneration, so that a better alopecia prevention and treatment effect is achieved; the pharmaceutical preparation prepared by selecting a specific filler, an adhesive, a sustained-release framework material and a lubricant in a reasonable proportioning range has good sustained-release performance, the dosage and frequency of the medicine are greatly reduced, and the side effect is far lower than that of an oral medicine in a common dosage form.

The invention discloses a preparation process and application of an astaxanthin, lycopene and procyanidine compound preparation for resisting aging and preventing prostatic diseases, and belongs to the field of health care products and biological medicines. The preparation is prepared from the following components in parts by weight: 1-10 parts of astaxanthin, 5-30 parts of procyanidine, 2-15 parts of lycopene, 0.5-3 parts of black cumin seed oil, 3-8 parts of phyllanthus emblica extract and 1-5 parts of South African drunken solanum extract, and is prepared by an efficient wet granulation technology. Through the synergistic effect of all the components, the antioxidant activity, the anti-inflammatory activity and the anti-cancer activity are remarkably improved, and the double effects of resisting aging and preventing and treating prostate diseases are achieved. Experiments show that the hydroxyl free radical scavenging rate of the compound preparation is increased by 2.3 times compared with that of a single prescription, inflammatory factors of a prostatitis model are reduced by 68%, the antioxidant capacity of skin is improved by 55%, and by combining with finasteride, the dosage of chemical drugs can be reduced by 80%, and the risk of sexual dysfunction is reduced. The black cumin seed oil obviously improves the bioavailability (29.7%) of lycopene, the prostate tissue drug concentration is 6.5 times that of blood, and low dosage and high benefit are achieved.

To provide a method for stimulating hair growth on the scalp of a human subject.SOLUTION: The present invention provides a method that includes the steps of: a) providing a topical composition comprising a therapeutically effective amount of dutasteride and / or finasteride, or pharmaceutically acceptable salts, esters, or derivatives thereof, and pharmaceutically acceptable topical excipients or carriers; and b) topically applying the composition to the scalp in an amount and for a duration sufficient to stimulate hair growth, wherein hair growth comprises an increase in scalp hair density, hair thickness, or scalp coverage.SELECTED DRAWING: Figure 1

The present invention discloses a preparation process and application of a compound preparation of astaxanthin, lycopene and proanthocyanidins for anti-aging and prevention of prostate diseases, belonging to the field of biomedicine. The preparation is composed of astaxanthin (1-10 parts), proanthocyanidins (5-30 parts), lycopene (2-15 parts), black cumin seed oil (0.5-3 parts), Phyllanthus emblica extract (3-8 parts) and Withania somnifera extract (1-5 parts), and is prepared by high-efficiency wet granulation technology. The components act synergistically to significantly enhance antioxidant, anti-inflammatory and anti-cancer activities, and have dual effects of anti-aging and prevention and treatment of prostate diseases. Experiments show that the hydroxyl radical scavenging rate of the compound preparation is 2.3 times higher than that of the single ingredient, the inflammatory factors in the prostatitis model are reduced by 68%, the skin antioxidant capacity is increased by 55%, and the combination with finasteride can reduce the dosage of chemical drugs by 80% and reduce the risk of sexual dysfunction. Black cumin seed oil significantly improves the bioavailability of lycopene (29.7%), and the drug concentration in the prostate tissue reaches 6.5 times that in the blood, achieving high efficiency with low dosage.

The invention relates to the field of biological medicine, in particular to application of finasteride in preparation of a medicine for treating triple negative breast cancer. In-vitro experiments prove that by up-regulating ZBTB20 gene expression, finasteride significantly inhibits polarization of macrophages to M2 type and promotes M1 type differentiation; a mouse triple-negative breast cancer transplantation tumor model further proves that the treatment of finasteride combined with adriamycin has an anti-tumor effect and can significantly inhibit tumor growth, so that the combination of finasteride and adriamycin can significantly enhance the anti-tumor effect and is superior to single-drug treatment. The invention discloses the application of finasteride in treatment of triple negative breast cancer for the first time, proposes the ZBTB20 gene as a main action target of finasteride in inhibition of triple negative breast cancer tumor, and proposes that the ZBTB20 protein or the ZBTB20 gene as a treatment target has great potential in treatment of triple negative breast cancer, drug screening and other aspects.

In one aspect, the disclosure relates to topical formulations, methods of making same, and methods of treating hair loss using same. In an aspect, the present disclosure pertains to topical formulations for treatment of hair loss and / or to increase hair growth, the formulation comprising: a therapeutic composition comprising therapeutically effective amounts of azelaic acid, minoxidil, finasteride, and dutasteride; and one or more compounding agents. In a further aspect, the present disclosure pertains to a method of treating hair loss by applying a disclosed topical formulation. In a further aspect, the present disclosure pertains to a method of enhancing hair grow by applying a disclosed topical formulation. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

The invention belongs to the field of medicines, and discloses a finasteride-containing composition and application thereof. The composition comprises finasteride, graphene and more than one pharmaceutically acceptable auxiliary material. The composition can well prevent and / or treat alopecia, alopecia seborrhoeica, androgenetic alopecia and alopecia areata or promote hair growth, compared with finasteride tablets, the dosage of active ingredients of the composition is greatly reduced, related side effects of the active ingredients are relieved, and the composition is quick in effect taking, long in drug effect lasting time and good in curative effect.

The invention provides a double-layer photo-thermal drug-loaded hydrogel microneedle, a preparation method thereof and application of the double-layer photo-thermal drug-loaded hydrogel microneedle in preparation of drugs for treating androgenetic alopecia, and belongs to the technical field of microneedle materials. The preparation method comprises the following steps: preparing a first precursor solution from prepared methacrylated hyaluronic acid, a polylactic acid-glycolic acid copolymer loaded with a finasteride drug and lithium phenyl-2, 4, 6-trimethylbenzoyl phosphonate, adding the first precursor solution into a needle body part of a microneedle mold, and performing negative pressure defoaming, heating concentration and light curing to form the needle body part; meanwhile, black phosphorus quantum dots and a methacrylated hyaluronic acid solution are mixed to prepare a second precursor solution, the second precursor solution is added into a needle body part of a microneedle mold to be dried, a substrate part is formed, and the double-layer photo-thermal drug-loading hydrogel microneedle is prepared. According to the double-layer photo-thermal drug-loading hydrogel microneedle, the drug release rate can be regulated and controlled through the photo-thermal effect of the black phosphorus quantum dots, and precise drug delivery is achieved.

According to the preparation method, sodium perborate tetrahydrate is selected as an oxidizing agent, the requirement for preparing the finasteride through an oxidation elimination reaction is met by accurately controlling reaction conditions, the impurity amount is small, a reagent which easily generates a large amount of waste solids or waste liquid is avoided, operation is easy, and the method is suitable for industrial production. Waste liquid generated by post-treatment is easy to treat. Meanwhile, side reactions are reduced, tedious refining steps are avoided, and the yield of the product is increased.

The invention relates to the related field of treatment of alopecia, in particular to a compound preparation for treating alopecia and a preparation technology of the compound preparation for treating alopecia. The first active component accounts for 1-10% by mass of the compound preparation, the second active component accounts for 0.1-5% by mass of the compound preparation, the first active component is minoxidil, and the second active component is finasteride. The compound preparation is a gel, plays a local role and is free of irritation, and the medicine can be better reserved to act on the scalp, so that the effect of treating alopecia is achieved.

A method for promoting hair regrowth in a subject includes performing microneedling on a region of a scalp of the subject to a depth of 0.5 millimeters (mm) to 1.5 mm, applying at least one therapeutic agent to the microneedled region, wherein the at least one therapeutic agent comprises Minoxidil, Finasteride, and Dutasteride, and implanting non-permanent pigment particles into a superficial dermis of the microneedled region, the microneedling, the applying, and the implanting together synergistically stimulating hair follicle activity.

The invention relates to the technical field of androgen-derived alopecia, and discloses a micro-needle patch based on a hierarchical targeting mechanism as well as a preparation method and application of the micro-needle patch. The finasteride is arranged on the needle tip section of the microneedle, the quercetin is arranged on the needle root section, different cells are targeted through the finasteride and the quercetin in a graded mode, and the microneedle patch with a graded targeting mechanism is formed. After the micro needle pierces into the skin, the water-soluble polymer at the needle tip section is dissolved, finasteride targeted hair papilla cells are released, and then in the process that finasteride acts, the quercetin slowly released at the needle root section gradually acts on endothelial cells in a targeted mode, the proliferation and migration activity of the endothelial cells is promoted, and the effect of the finasteride on the skin is achieved. Endothelial cells are enhanced to form a highly branched capillary network to act on hair papilla cells, the metabolic demand of the hair papilla cells is maintained, and finally the effect of enhancing the finasteride targeting effect is achieved. Therefore, the microneedle patch with the hierarchical targeting mechanism has an excellent AGA curative effect.

Provided is a pharmaceutical composition for preventing or treating benign prostatic hyperplasia or alopecia, comprising lactic acid bacteria of Enterococcus genus as an active ingredient. The pharmaceutical composition of the present invention can replace the conventional therapeutic agents against treating benign prostatic hyperplasia or alopecia, such as finasteride or dutasteride. In particular, by introducing heat-killed probiotics of Enterococcus faecalis, the effect of preventing or treating benign prostatic hyperplasia or alopecia can be further enhanced.

This invention provides a topical finasteride formulation and its preparation method, belonging to the field of pharmaceutical formulation technology. The topical finasteride formulation provided by this invention is a topical dosage form, comprising finasteride and excipients; after scalp administration, the concentration in hair follicles and the epidermis is 999-5021 pg / mL, and the systemic blood concentration is 17.1-178.9 pg / mL; the systemic blood concentration is 1-10% of that of oral finasteride formulations. The method involves preparing finasteride and excipients, followed by steps of dissolving / preparing the matrix, fine filtration / homogenization, and filling to obtain finasteride topical formulations of different dosage forms. This invention effectively solves the shortcomings of existing finasteride formulations, such as high systemic absorption, high risk of adverse reactions, and difficulty in industrializing the process, making it suitable for large-scale clinical application in androgenetic alopecia, combining efficacy and safety.

In one aspect, the disclosure relates to topical formulations, methods of making same, and methods of treating hair loss using same. In an aspect, the present disclosure pertains to topical formulations for treatment of hair loss and / or to increase hair growth, the formulation comprising: a therapeutic composition comprising therapeutically effective amounts of azelaic acid, minoxidil, finasteride, and dutasteride; and one or more compounding agents. In a further aspect, the present disclosure pertains to a method of treating hair loss by applying a disclosed topical formulation. In a further aspect, the present disclosure pertains to a method of enhancing hair grow by applying a disclosed topical formulation. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

The invention discloses a preparation method of a photo-crosslinking hydrogel microneedle loaded with a finasteride drug, which comprises the following three steps: preparing drug nanoparticles, synthesizing a hydrogel precursor and preparing the photo-crosslinking hydrogel microneedle. The preparation method specifically comprises the steps of preparing finasteride (FIN)-loaded polyhydroxyalkanoate (PHA) nanoparticles (F-PHANPs), preparing F-PHANPs-loaded HAMA hydrogel (F-HAMA) and preparing a hydrogel microneedle, introduction of the F-PHANPs enhances the mechanical performance of the hydrogel, meanwhile, the hardness is remarkably enhanced, and the hydrogel has excellent drug release performance and biocompatibility and can be used for preparing the hydrogel microneedle. Potential application prospects are shown in the field of treating androgenetic alopecia through transdermal drug delivery.

A method for the treatment or prevention of the symptoms or effects of hair loss of an animal which comprises treating the animal with a therapeutically effective amount of a combination comprising 7α-Acetylthio-17α-hydroxy-3-oxopregn-4-ene-21-carboxylic acid γ-lactone or a physiologically functional derivative thereof, N-[2,5-bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide or a physiologically functional derivative thereof, 17β-(N-tert-butylcarbamoyl)-4-aza-5α-androst-1-en-3-one or a physiologically functional derivative thereof, and 2,4-pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide or a physiologically functional derivative thereof. A pharmaceutical formulation comprising the same. A patient pack comprising at least one active ingredient selected from 7α-Acetylthio-17α-hydroxy-3-oxopregn-4-ene-21-carboxylic acid γ-lactone or a physiologically functional derivative thereof, N-[2,5-bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide, 17β-(N-tert-butylcarbamoyl)-4-aza-5α-androst-1-en-3-one, and 2,4-pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide, and an information insert containing directions on the use of all three active ingredients together in combination.

An embodiment relates to a novel long-acting injectable composition for preventing or treating androgenetic alopecia containing finasteride. The injectable composition is capable of inhibiting type II 5α-reductase for one month or more with a single injection, thereby limiting the conversion of testosterone to DHT and inhibiting androgen-mediated hair follicle miniaturization. In addition, the injectable composition may increase the mean elimination half-life (t1 / 2el) of finasteride after in vivo injection, thereby increasing the stability of finasteride, and exhibiting a more predictable and uniform therapeutic effect compared to oral dosage forms.